Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer’s disease

Purpose To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. Methods Two independent dementia experts provided eti...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2020-02, Vol.47 (2), p.270-280
Main Authors: Ramusino, Matteo Cotta, Garibotto, Valentina, Bacchin, Ruggero, Altomare, Daniele, Dodich, Alessandra, Assal, Frederic, Mendes, Aline, Costa, Alfredo, Tinazzi, Michele, Morbelli, Silvia D., Bauckneht, Matteo, Picco, Agnese, Dottorini, Massimo E., Tranfaglia, Cristina, Farotti, Lucia, Salvadori, Nicola, Moretti, Davide, Savelli, Giordano, Tarallo, Anna, Nobili, Flavio, Parapini, Maura, Cavaliere, Carlo, Salvatore, Elena, Salvatore, Marco, Boccardi, Marina, Frisoni, Giovanni B
Format: Article
Language:English
Subjects:
Algorithms
Alzheimer Disease - diagnostic imaging
Alzheimer's disease
Amyloid beta-Peptides
Biomarkers
Cardiology
Cerebrospinal fluid
Cognitive ability
Cognitive Dysfunction - diagnostic imaging
Dementia
Dementia disorders
Diagnosis
Diagnostic systems
Etiology
Humans
Imaging
Magnetic resonance imaging
Medical diagnosis
Medicine
Medicine & Public Health
Neurology
Nuclear Medicine
Oncology
Original Article
Orthopedics
Peptide Fragments
Positron emission tomography
Radiology
Tau protein
tau Proteins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To compare the incremental diagnostic value of amyloid-PET and CSF (Aβ42, tau, and phospho-tau) in AD diagnosis in patients with mild cognitive impairment (MCI) or mild dementia, in order to improve the definition of diagnostic algorithm. Methods Two independent dementia experts provided etiological diagnosis and relative diagnostic confidence in 71 patients on 3 rounds, based on (1) clinical, neuropsychological, and structural MRI information alone; (2) adding one biomarker (CSF amyloid and tau levels or amyloid-PET with a balanced randomized design); and (3) adding the other biomarker. Results Among patients with a pre-biomarker diagnosis of AD, negative PET induced significantly more diagnostic changes than amyloid-negative CSF at both rounds 2 (CSF 67%, PET 100%, P  = 0.028) and 3 (CSF 0%; PET 78%, P  
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-019-04466-6